Key facts
- ACM Biolabs’s last known valuation is $92.7M (Sep 2022).
- It has raised $26.0M; the latest was Later Stage VC ($2.9M) in May 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Coalition for Epidemic Preparedness Innovations, San Pacific Investments, Agency for Science, NTUitive — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ACM Biolabs
- ·The full record, as it builds
Funding rounds
No funding rounds for ACM Biolabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ACM Biolabs
Operator of a biotechnology company intended to develop novel vaccines using proprietary artificial cell membrane technology. The company develops prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, enabling medical researchers to develop effective vaccines.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2013
- Employees
- 19
- Website
- acmbiolabs.com/
- Ownership
- Privately Held (backing)
ACM Biolabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ACM Biolabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ACM Biolabs in its N-PORT filings yet. We sweep new filings monthly.